ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Research Topic : diagnostic methods
Scheme : NHMRC Development Grants
Clear All
Filter by Field of Research
Diagnostic Applications (3)
Medical Biotechnology Diagnostics (incl. Biosensors) (2)
Respiratory Diseases (2)
Clinical microbiology (1)
Developmental Genetics (incl. Sex Determination) (1)
Genetics Not Elsewhere Classified (1)
Humoural Immunology and Immunochemistry (1)
Medical and Health Sciences (1)
Neurology And Neuromuscular Diseases (1)
Neurology and Neuromuscular Diseases (1)
Nutrigenomics and personalised nutrition (1)
Optometry and Ophthalmology (1)
Radiology and Organ Imaging (1)
Radiotherapy And Nuclear Medicine (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (19)
Filter by Status
Closed (19)
Filter by Scheme
NHMRC Development Grants (19)
Filter by Country
Australia (1)
Filter by Australian State/Territory
VIC (1)
  • Researchers (0)
  • Funded Activities (19)
  • Organisations (9)
  • Funded Activity

    A New Non-invasive Diagnostic Technique Based On Detection Of Exhaled Respiratory Pathogens.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $179,300.00
    Summary
    We developed a special collection mask and showed that the breath of people with colds or flu contains a tiny amount of virus. Currently, diagnostic samples are collected by putting a tube into the airways - this is very uncomfortable. Our masks may provide a new and more comfortable way to diagnose lung infections. We want to build better masks and ways to detect viruses and bacteria to test out this method. This may create a new test that will improve diagnosis and treatment.
    More information
    Funded Activity

    Rapid, Cost-effective, Diagnosis And Monitoring Of Multiple Sclerosis By Novel Multifocal Evoked Potential Methods

    Funder
    National Health and Medical Research Council
    Funding Amount
    $152,463.00
    Summary
    A new technology for concurrently stimulating both eyes, and recording thousands of responses from the brain, will be tested for its effectiveness in diagnosing and tracking progression in Multiple Sclerosis (MS), and the degree to which it complements Magnetic Resonance Imaging (MRI). Our understanding of MS has changed in recent years. It is now recognised to have two phases: an initial inflammatory phase, and a secondary progressive phase. The progressive phase produces the inexorable increas .... A new technology for concurrently stimulating both eyes, and recording thousands of responses from the brain, will be tested for its effectiveness in diagnosing and tracking progression in Multiple Sclerosis (MS), and the degree to which it complements Magnetic Resonance Imaging (MRI). Our understanding of MS has changed in recent years. It is now recognised to have two phases: an initial inflammatory phase, and a secondary progressive phase. The progressive phase produces the inexorable increasing disability of MS. MS only affects about 0.04% of Australians but the early onset of MS, the high cost of medication, and the prolonged period of disability, mean that the cost to Australia is about $2 billion pa. MRI quantifies the inflammatory phase well but is poorly correlated with the debilitating secondary progression. The common treatments for MS target the inflammatory phase but not the causes of secondary progression, which are unknown. Current diagnostic methods mean diagnosis can take years, meaning that patients can be denied treatment for some time. The applicants have published experiments on 50 MS patients and 27 normal subjects using a variant of the new method. Not only has it shown high diagnostic accuracy, but the new method seems to provide data on the progressive phase, suggesting strongly that it is complementary to MRI. The new method is also much cheaper to set up and run than MRI and so could provide cost-effective means for monitoring patient condition and testing new drugs that are effective against the progressive phase. The applicants have considerable experience commercialising diagnostic technologies, and are currently working with an Australian company developing new diagnostic hardware. That hardware has been adapted to perform the presently proposed experiments. Overall it is reasonable to assume that positive outcomes will be translated into economic and health benefits for Australians.
    Read more Read less
    More information
    Funded Activity

    Oxidation Of Mismatch: A New Concept For Mutation Detection Which Avoides A Separation Method In Mutation Scanning

    Funder
    National Health and Medical Research Council
    Funding Amount
    $143,000.00
    Summary
    Detection of faults (mutations) in genes is expensive but essential for proper genetic health care. Because of the cost of such tests many people are not diagnosed either through diagnostic labs or research of the cost of such tests many people are not diagnosed either through diagnostic labs or research projects. Such research projects are inhibited due to the complexity of the current methods. Current methods are complex and expensive, especially looking for a possible fault, due to what is ca .... Detection of faults (mutations) in genes is expensive but essential for proper genetic health care. Because of the cost of such tests many people are not diagnosed either through diagnostic labs or research of the cost of such tests many people are not diagnosed either through diagnostic labs or research projects. Such research projects are inhibited due to the complexity of the current methods. Current methods are complex and expensive, especially looking for a possible fault, due to what is called a preparation step on complex and expensive equipment. We will develop and commercialise a simpler test because separation is avoided.
    Read more Read less
    More information
    Funded Activity

    Development Of A Novel Biosensor Using Magnetically Amplified Luminescence For The Early Detection Of Cancer

    Funder
    National Health and Medical Research Council
    Funding Amount
    $267,500.00
    Summary
    Cancer is often not detected until it has invaded surrounding tissues and spread to other organs. Current treatment is then often ineffective, and prognosis poor. Early detection of cancer is therefore essential for improved disease management. Such methods must be cheap, non-invasive, and rapid with high sensitivity and specificity. We are investigating a new biosensor technology that satisfies these criteria. This method uses magnetically amplified luminescence for the detection of low levels .... Cancer is often not detected until it has invaded surrounding tissues and spread to other organs. Current treatment is then often ineffective, and prognosis poor. Early detection of cancer is therefore essential for improved disease management. Such methods must be cheap, non-invasive, and rapid with high sensitivity and specificity. We are investigating a new biosensor technology that satisfies these criteria. This method uses magnetically amplified luminescence for the detection of low levels of cancer cells in clinical samples (urine, faeces, blood, biopsy), using telomerase as a marker.
    Read more Read less
    More information
    Funded Activity

    A Novel Non-invasive Diagnostic Imaging Technique Of Metastatic Cancer Using Plasminogen Activator Inhibitor Type 2.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $187,750.00
    Summary
    This project aims to develop a non-invasive tumour diagnostic imaging agent based on a non-toxic protein (PAI2) that we know specifically identifies a critical marker of malignancy. PAI2 will be labelled with commonly used imaging radioisotopes. This novel imaging technique has important potential clinical uses including, determination of the most appropriate treatment for individual patients, assessing the success of such treatments, and a novel non-invasive prognostic indicator of malignancy.
    More information
    Funded Activity

    Development Of A Novel Diagnostic Test For The Death Of Neuromelanin-containing Dopamine Neurons In The Human Brain

    Funder
    National Health and Medical Research Council
    Funding Amount
    $325,308.00
    More information
    Funded Activity

    Novel Genes And Protein In Non-alcoholic Fatty Liver Disease: Potential Basis Of A Serum-based Assessment Of Disease Sta

    Funder
    National Health and Medical Research Council
    Funding Amount
    $200,000.00
    Summary
    The most common cause of elevated liver function tests is non-alcoholic fatty liver disease (NAFLD). NALFD is a spectrum of disease ranging from steatosis, to non-alcoholic steatohepatitis (NASH), a condition associated with the development of fibrosis in the majority of individuals. Approximately 20% and 3% of adults are affected with NAFLD and NASH, respectively, and NAFLD is expected to become the next major liver epidemic facing the western world, far exceeding the prevalence of chronic infe .... The most common cause of elevated liver function tests is non-alcoholic fatty liver disease (NAFLD). NALFD is a spectrum of disease ranging from steatosis, to non-alcoholic steatohepatitis (NASH), a condition associated with the development of fibrosis in the majority of individuals. Approximately 20% and 3% of adults are affected with NAFLD and NASH, respectively, and NAFLD is expected to become the next major liver epidemic facing the western world, far exceeding the prevalence of chronic infection with the hepatitis C virus. We obtained liver biopsies from patients with NAFLD, 80% of whom had NASH, and determined the expression profile analysis of each subject using 19,200 element microarrays. Our data demonstrates the concordant differential expression of 130 genes, in subjects with NAFLD that were categorizes into 6 major metabolic and regulatory pathways. Many of these genes represented uncharacterised genes. Utilising an extensive bioinformatics approach we have been able to define the genes and their protein product. The use of these proteins as a diagnostic tool for the detection of NAFLD forms the basis of a provisional patent application. However, measurements of protein levels in tissue and sera from patients with NAFLD are needed for the development of a diagnostic method. Such information would also provide significant insight into the pathogenesis of NAFLD. The AIMS are: 1)                  Production of antibodies against proteins encoded by candidate genes                  Expression profile of candidate genes 3)                  Expression of proteins encoded by candidate genes in patients with NAFLD
    Read more Read less
    More information
    Funded Activity

    Binocular Objective Visual Field Testing Using Pupillography

    Funder
    National Health and Medical Research Council
    Funding Amount
    $113,487.00
    More information
    Funded Activity

    A Novel One-step Approach In The Early Diagnosis Of Prostate Cancer

    Funder
    National Health and Medical Research Council
    Funding Amount
    $102,150.00
    Summary
    In order to avoid the invasiveness and imprecision of current prostate cancer detection, this programme is directed to developing a non-invasive and repeatable, accurate approach. This research project is designed to optimise retrieval of prostate cells from ejaculate and to compare two methods for profiling selected genetic changes to diagnose prostate cancer. The refinement of techniques, outlined in the application, is essential before proceeding to a clinical trial.
    More information
    Funded Activity

    Development Of An Assay To Distinguish Between Recent And Established HIV-1 Infection

    Funder
    National Health and Medical Research Council
    Funding Amount
    $192,500.00
    Summary
    We have discovered a marker of recent HIV infection. Further refinement of this assay and fully evaluating it on samples from individuals infected with different subtypes of the virus will result in an HIV incidence assay ready for commercialisation. An assay capable of distinguishing between recently acquired and established HIV infection would be most valuable in establishing the incidence of infection for epidemiological surveys, to clearly identify new infections following vaccine trials and .... We have discovered a marker of recent HIV infection. Further refinement of this assay and fully evaluating it on samples from individuals infected with different subtypes of the virus will result in an HIV incidence assay ready for commercialisation. An assay capable of distinguishing between recently acquired and established HIV infection would be most valuable in establishing the incidence of infection for epidemiological surveys, to clearly identify new infections following vaccine trials and identify HIV infection as opposed to transfer of maternal antibodies in new born infants.
    Read more Read less
    More information

    Showing 1-10 of 19 Funded Activites

    • 1
    • 2
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback